PL2356269T3 - Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania - Google Patents

Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania

Info

Publication number
PL2356269T3
PL2356269T3 PL09824067.4T PL09824067T PL2356269T3 PL 2356269 T3 PL2356269 T3 PL 2356269T3 PL 09824067 T PL09824067 T PL 09824067T PL 2356269 T3 PL2356269 T3 PL 2356269T3
Authority
PL
Poland
Prior art keywords
methods
type iii
domain based
fibronectin type
iii domain
Prior art date
Application number
PL09824067.4T
Other languages
English (en)
Inventor
Steven Jacobs
Karyn O'neil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2356269T3 publication Critical patent/PL2356269T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
PL09824067.4T 2008-10-31 2009-10-27 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania PL2356269T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11012008P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
PL2356269T3 true PL2356269T3 (pl) 2016-12-30

Family

ID=42129528

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09824067.4T PL2356269T3 (pl) 2008-10-31 2009-10-27 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania

Country Status (23)

Country Link
US (6) US8278419B2 (pl)
EP (2) EP2356269B1 (pl)
JP (3) JP5848607B2 (pl)
KR (1) KR101781907B1 (pl)
CN (1) CN102307896B (pl)
AU (3) AU2009308935B2 (pl)
BR (1) BRPI0919881B1 (pl)
CA (2) CA2741834C (pl)
CY (1) CY1118120T1 (pl)
DK (1) DK2356269T3 (pl)
EA (1) EA028304B1 (pl)
ES (2) ES2595504T3 (pl)
HR (1) HRP20161251T1 (pl)
HU (1) HUE030471T2 (pl)
IL (4) IL212531A (pl)
LT (1) LT2356269T (pl)
MX (1) MX2011004550A (pl)
PL (1) PL2356269T3 (pl)
PT (1) PT2356269T (pl)
RS (1) RS55218B1 (pl)
SI (1) SI2356269T1 (pl)
SM (1) SMT201600312B (pl)
WO (1) WO2010051274A2 (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
EP3156415A1 (en) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2009058379A2 (en) 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396011B1 (en) * 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
CA2795325A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP3569256B1 (en) * 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
AU2015271900B2 (en) * 2010-04-30 2017-02-02 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
US9096984B2 (en) 2010-12-07 2015-08-04 The Trustees Of Columbia University In The City Of New York Network material devices, methods, and systems
WO2012103347A1 (en) * 2011-01-26 2012-08-02 Whitson Stanley William Hydrogel bioscaffold and coating for bone and tooth repair
PT2697257T (pt) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
ES2848531T3 (es) 2011-05-17 2021-08-10 Bristol Myers Squibb Co Métodos mejorados para la selección de proteínas de unión
BR112014007469B1 (pt) 2011-09-27 2022-06-14 Janssen Biotech, Inc Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína
RU2019133467A (ru) 2011-10-11 2020-07-06 МЕДИММЬЮН, ЭлЭлСи Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
EP2855509B1 (en) * 2012-05-25 2018-05-02 Janssen Biotech, Inc. Non-natural consensus albumin binding domains
CN108409856B (zh) 2012-09-13 2022-03-04 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SI2922872T1 (sl) 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (en) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
EP3299378B1 (en) 2013-02-12 2019-07-31 Bristol-Myers Squibb Company High ph protein refolding methods
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AU2014334627B2 (en) 2013-10-14 2019-07-25 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
KR20220162886A (ko) 2014-03-20 2022-12-08 브리스톨-마이어스 스큅 컴퍼니 혈청 알부민-결합 피브로넥틴 유형 iii 도메인
AU2015231210B2 (en) * 2014-03-20 2019-09-12 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
KR102632830B1 (ko) 2014-09-03 2024-02-02 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US10564148B2 (en) 2014-09-24 2020-02-18 Triad National Security, Llc Multi-organ media compositions and methods of their use
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
EP3268389B1 (en) 2015-03-12 2020-09-30 Medimmune, LLC Method of purifying albumin-fusion proteins
KR20170138558A (ko) 2015-04-24 2017-12-15 비브 헬스케어 유케이 (넘버5) 리미티드 Hiv 융합을 표적으로 하는 폴리펩티드
EA201792441A2 (ru) 2015-05-06 2018-06-29 Янссен Байотек, Инк. Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
WO2016179518A2 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
DK3337824T3 (da) 2015-08-17 2020-08-24 Janssen Pharmaceutica Nv Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
US11124791B2 (en) 2015-09-14 2021-09-21 Arizona Board Of Regents On Behalf Of Arizona State University Generating recombinant affinity reagents with arrayed targets
JP6893504B2 (ja) 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン
MA43164A (fr) 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
WO2017188215A1 (ja) * 2016-04-27 2017-11-02 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
MA45186A (fr) * 2016-06-03 2019-04-10 Janssen Biotech Inc Domaines de fibronectine de type iii se liant à l'albumine sérique
US10662235B2 (en) 2016-06-21 2020-05-26 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
JP7088932B2 (ja) 2016-09-14 2022-06-21 ヤンセン バイオテツク，インコーポレーテツド Ｂｃｍａ特異的フィブロネクチンｉｉｉ型ドメインを有するキメラ抗原受容体、及びその使用
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018111978A1 (en) * 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111973A1 (en) * 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
TW202320794A (zh) 2017-02-28 2023-06-01 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
MA49652A (fr) 2017-07-17 2020-05-27 Janssen Biotech Inc Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation
CA3074317A1 (en) * 2017-08-25 2019-02-28 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
CN110276503B (zh) * 2018-03-14 2023-04-21 吉旗物联科技（上海）有限公司 一种自动识别冷链车辆任务的方法
KR101995774B1 (ko) * 2018-05-08 2019-07-03 한국세라믹기술원 뎅기열 바이러스에 특이적으로 결합하는 피브로넥틴 edb 단백질 스캐폴드
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
WO2020191306A1 (en) 2019-03-21 2020-09-24 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
TW202102506A (zh) 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
TW202106691A (zh) 2019-04-26 2021-02-16 美商伊繆諾金公司 喜樹鹼衍生物
AU2020313521A1 (en) 2019-07-12 2022-02-17 Janssen Pharmaceutica Nv Binding agents and uses thereof
CN114786682A (zh) 2019-10-14 2022-07-22 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
CN115666630A (zh) * 2020-04-08 2023-01-31 诺斯楚姆制药有限责任公司 使用干扰素治疗呼吸道病毒感染的组成物和方法
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
JP2023551388A (ja) 2020-11-10 2023-12-08 ニューヨーク・ユニバーシティ マクロピノサイトーシス選択的モノボディ－薬物コンジュゲート
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
JP2024506694A (ja) 2021-02-16 2024-02-14 ヤンセン バイオテツク，インコーポレーテツド 増強されたリンカー標的化のための材料及び方法
US20220306738A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
CN117377694A (zh) 2021-03-24 2024-01-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
BR112023019484A2 (pt) 2021-03-24 2023-12-05 Janssen Biotech Inc Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0600866T3 (da) 1990-06-01 1998-03-09 Chiron Corp Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
ATE359842T1 (de) 1991-07-02 2007-05-15 Nektar Therapeutics Abgabevorrichtung für nebelförmige medikamente
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
ATE174804T1 (de) 1992-10-19 1999-01-15 Dura Pharma Inc Trockenpulverinhalator
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DK0680451T3 (da) 1993-01-19 1999-07-19 Glaxo Group Ltd Aerosoldispenser samt fremgangsmåde ved dens fremstilling
DE69434437T2 (de) * 1993-02-05 2006-04-06 Smithkline Beecham P.L.C., Brentford Fibronektinbindungsprotein, monoklonaler antikoerper und ihre verwendung zur verhuetung der adhäsion von bakterien
CA2155728C (en) 1993-02-12 2000-04-25 Gerald R. Crabtree Regulated transcription of targeted genes and other biological events
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
EA001016B1 (ru) 1996-01-03 2000-08-28 Глаксо Груп Лимитед Ингаляционное устройство
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP1015576B1 (en) 1997-09-16 2005-05-04 Egea Biosciences, LLC Method for the complete chemical synthesis and assembly of genes and genomes
AU757153B2 (en) 1997-09-29 2003-02-06 Novartis Ag Stabilized preparations for use in metered dose inhalers
US6846655B1 (en) * 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ES2564161T3 (es) * 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
AU2002213251B2 (en) * 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
GB0119476D0 (en) * 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
DE60335000D1 (de) 2002-09-06 2010-12-30 Isogenica Ltd In vitro peptid-expressionsbank
WO2004029224A2 (en) 2002-09-30 2004-04-08 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005056754A2 (en) 2003-11-19 2005-06-23 The Scripps Research Institute Compositions and methods to reduce mutagenesis
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
CN1946417A (zh) * 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
US20060040278A1 (en) * 2004-01-27 2006-02-23 Cojocaru Gad S Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
SG134283A1 (en) * 2006-01-24 2007-08-29 Ind Tech Res Inst Biomarkers for liver fibrotic injury
JP2009523459A (ja) 2006-01-24 2009-06-25 ドマンティス リミテッド 天然の連結部を含有する融合タンパク質
WO2008079973A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
US20110009323A1 (en) 2007-06-15 2011-01-13 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
WO2009058379A2 (en) 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
WO2009086116A2 (en) 2007-12-19 2009-07-09 Centocor, Inc. Alternative scaffold protein fusions phage display via fusion to plx of m13 phage
ES2620285T3 (es) 2008-05-02 2017-06-28 Novartis Ag Moléculas de unión con base en fibronectina mejorada y usos de las mismas
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396011B1 (en) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2452165A1 (en) 2009-07-07 2012-05-16 Siemens AG Apparatus and method for measuring multi-phase fluid flow
EP3569256B1 (en) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
EP2598529A2 (en) 2010-07-30 2013-06-05 Novartis AG Fibronectin cradle molecules and libraries thereof

Also Published As

Publication number Publication date
KR20110079912A (ko) 2011-07-11
WO2010051274A2 (en) 2010-05-06
US10040842B2 (en) 2018-08-07
IL232095A0 (en) 2014-05-28
US11479880B2 (en) 2022-10-25
BRPI0919881B1 (pt) 2021-09-08
EP2356269A2 (en) 2011-08-17
AU2009308935A1 (en) 2010-05-06
US8278419B2 (en) 2012-10-02
CA2741834A1 (en) 2010-05-06
ES2595504T3 (es) 2016-12-30
US10654913B2 (en) 2020-05-19
LT2356269T (lt) 2016-09-12
KR101781907B1 (ko) 2017-09-26
BRPI0919881A2 (pt) 2016-02-16
US20180334492A1 (en) 2018-11-22
HRP20161251T1 (hr) 2016-11-18
IL232095A (en) 2017-05-29
US20130096019A1 (en) 2013-04-18
EP2356269A4 (en) 2013-01-09
CN102307896B (zh) 2016-10-12
EA028304B1 (ru) 2017-11-30
CA3149920A1 (en) 2010-05-06
IL232094A (en) 2017-05-29
JP2017141265A (ja) 2017-08-17
HUE030471T2 (en) 2017-05-29
PT2356269T (pt) 2016-09-13
US9200059B2 (en) 2015-12-01
EP3128048B1 (en) 2018-11-28
IL212531A0 (en) 2011-06-30
AU2015202864A1 (en) 2015-06-18
JP5848607B2 (ja) 2016-01-27
CY1118120T1 (el) 2017-06-28
CN102307896A (zh) 2012-01-04
US20230071749A1 (en) 2023-03-09
JP6124267B2 (ja) 2017-05-10
MX2011004550A (es) 2011-07-20
AU2009308935B2 (en) 2015-02-26
CA2741834C (en) 2022-04-05
DK2356269T3 (en) 2016-08-15
JP2015205897A (ja) 2015-11-19
SMT201600312B (it) 2016-11-10
WO2010051274A3 (en) 2010-09-10
EA201170635A1 (ru) 2011-12-30
IL212531A (en) 2016-07-31
ES2705714T3 (es) 2019-03-26
US20200291094A1 (en) 2020-09-17
SI2356269T1 (sl) 2016-10-28
US20100216708A1 (en) 2010-08-26
IL232094A0 (en) 2014-05-28
EP2356269B1 (en) 2016-06-29
US20160039909A1 (en) 2016-02-11
JP2012507295A (ja) 2012-03-29
JP6599394B2 (ja) 2019-10-30
EP3128048A1 (en) 2017-02-08
IL232093A0 (en) 2014-05-28
RS55218B1 (sr) 2017-02-28
AU2017236012A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL232093A0 (en) Preparations based on type iii fibronectin ether scaffold, methods and uses
IL214539A0 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
EP2362879A4 (en) FIELD-BASED SCAFFOLD COMPOSITIONS OF ANTI-TNF-ALPHA TYPE III FIBRONECTIN, METHODS AND USES
IL242192A (en) Certain chemicals, preparations and methods
IL222573A0 (en) Stabilized fibronectin domain compositions, methods and uses
IL210559A0 (en) Novel compositions and methods
IL210588A0 (en) Novel compositions and methods
ZA201005780B (en) Certain chemical entities,compositions and methods
GB0817585D0 (en) Novel compositions and methods
HK1149770A1 (en) Compositions, methods and kits
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods